Sanofi va acquérir Amunix pour son portefeuille en immuno-oncologie avec une nouvelle génération d’agents biologiques à activation conditionnelle
20 déc. 2021 23h30 HE
|
Sanofi - Aventis Groupe
Sanofi va acquérir Amunix pour son portefeuille en immuno-oncologie avec une nouvelle génération d’agents biologiques à activation conditionnelle Une opération qui apporte un portefeuille...
Sanofi to acquire Amunix immuno-oncology pipeline with next generation Conditionally Activated Biologics
20 déc. 2021 23h30 HE
|
Sanofi - Aventis Groupe
Sanofi to acquire Amunix immuno-oncology pipeline with next generation Conditionally Activated Biologics Adds promising pipeline of T-cell engagers and cytokine therapies with lead candidate...
Amunix Presents Preclinical Data on Its XPAT T Cell Engager Platform at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics
07 oct. 2021 09h00 HE
|
Amunix Pharmaceuticals, Inc.
AMX-818, an HER2-targeted T cell engager (TCE), is the lead program in Amunix’s XPAT® (XTENylated Protease-Activated TCE) platform designed to improve the therapeutic index of TCEs for the treatment...
Amunix Appoints Industry Veteran, Frank Watanabe, to its Board of Directors
23 juin 2021 07h00 HE
|
Amunix Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., June 23, 2021 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”), an immuno-oncology company leveraging its proprietary, clinically validated Pro-XTEN...
Amunix Announces the Appointment of Healthcare Investment Banking Veteran Zeeshan Merchant as Chief Financial Officer and Trisha Millican to the Board of Directors
26 janv. 2021 07h00 HE
|
Amunix Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on developing prodrugs to bring the promise of potent...
Amunix to Present Preclinical Data on Protease-Activated HER2- and EGFR-Targeted T Cell Engagers at ESMO Virtual Congress 2020
17 sept. 2020 07h00 HE
|
Amunix Pharmaceuticals, Inc.
– Data demonstrate potential of Amunix’s XPAT platform to mitigate on-target, off-tumor toxicity that has hindered success of T cell engagers in treating solid tumors – – Masked prodrug...
Amunix to Present Preclinical Data on HER2- and EGFR-Targeted T Cell Engagers at AACR Virtual Annual Meeting II
22 juin 2020 09h00 HE
|
Amunix Pharmaceuticals, Inc.
Data demonstrate potential of Amunix’s XPAT platform to significantly widen therapeutic index, and address on-target, off-tumor toxicity that has hindered application of T cell engagers to treat solid...
Amunix Appoints Anne Keane as Senior Vice President of Regulatory and Quality
27 mai 2020 07h00 HE
|
Amunix Pharmaceuticals, Inc.
MOUNTAIN VIEW, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on developing prodrugs to bring the promise of potent...
Amunix Raises $73 Million in Series A Financing Led by Omega Funds
04 mars 2020 07h00 HE
|
Amunix Pharmaceuticals, Inc.
-- Harnessing clinically validated prodrug technology to advance novel pipeline of T cell engager and cytokine agents that are selectively activated in the tumor microenvironment -- -- Proprietary T...
Amunix Pharmaceuticals Announces the Appointment of Dr. Maninder Hora as Chief Technical Operations Officer
27 août 2019 07h03 HE
|
Amunix Pharmaceuticals, Inc.
MOUNTAIN VIEW, Calif., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on enabling the promise of potent immune-activating...